03/03/2026 - Press release
They are part of the sixty research grants awarded by the organization, with total funding of more than thirteen million euros. The Spanish Association Against Cancer has awarded three of its research grants to projects led by researchers from the Hospital del Mar Research Institute (HMRIB). In total, sixty grants have been awarded: 54 to research projects and six accreditations to research centers. Altogether, this represents an investment in research of more than thirteen million euros.
27/02/2026 - Press release
High levels of this protein, which is part of blood cholesterol, are associated with a 40% higher probability of multivessel coronary atherosclerosis, directly linked to the risk of heart attack or other cardiac events. The findings come from a study led by researchers at the Hospital del Mar Research Institute and published in the American Journal of Preventive Cardiology. The authors advocate measuring lipoprotein(a) levels in all patients, not only those at high cardiovascular risk. This can be done through a simple blood test.
26/02/2026 - Press release
The Faculty Board elected him on February 10, and he officially took office on February 25. Dr. Joan Ramon Masclans, Head of the Intensive Care Medicine Department at Hospital del Mar, Coordinator of the Critical Care Pathology Research Group at the Hospital del Mar Research Institute, and Director of Teaching at the hospital, has once again been elected Dean of the Faculty of Medicine and Life Sciences at Universitat Pompeu Fabra. He will serve in the position for the next six years
18/02/2026 - Press release
A European macro-study, published in The Lancet Regional Health-Europe, analyzes disease trajectories, associated conditions, and survival among people with cancer. Hospital del Mar and the Hospital del Mar Research Institute took part in the research, which evaluates real-world clinical data from a cohort of more than 1.7 million patients from eight European countries. The most frequent cancers in Europe are breast, prostate, colorectal, and lung cancer. The highest survival rates a re seen in breast and prostate cancer, while pancreatic cancer has the poorest prognosis. Databases from Spain, Estonia, and Switzerland show the best survival rates.
Més informació "A large-scale study analyzes the evolution of the most common cancers in Europe"
05/02/2026 - Press release
A recent study from the Hospital del Mar Research Institute shows that cannabis use is associated with increased brain inflammation, which may affect the therapeutic effectiveness of antipsychotic treatments. The study analysed brain MRI scans from nearly 100 individuals-patients with first-episode psychosis and healthy volunteers-using a novel technique that measures extracellular free water. This is the first study to apply this method to examine the effects of cannabis use in psychosis. The findings are published in Molecular Psychiatry and reinforce recommendations against cannabis use in people with psychotic disorders.
Més informació "Cannabis use may influence treatment mechanisms in first-episode psychosis"
05/02/2026 - Press release
Infections caused by Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii are identified as priorities for clinical research. The study, published in the Journal of Infection and Public Health, involved 60 experts who reached consensus on the main priorities for the development of new clinical trials. The work carried out within the MePRAM project of CIBER has resulted in several priority lists-microorganisms, clinical syndromes, patient populations and anti-infective treatments-aimed at guiding future research from a personalised medicine approach.
Més informació "The roadmap for clinical research against antibiotic resistance established"
03/02/2026 - Press release
A research team from the Parc Taulí Research and Innovation Institute (I3PT), in collaboration with the Pere Virgili Health Research Institute (IISPV) and the Hospital del Mar Research Institute (HMRIB), has identified a clear association between the accumulation of abdominal fat and premature vascular aging in people with type 1 diabetes who have no previous history of cardiovascular disease. The research was based on a cohort of 179 individuals with this condition, all of whom were assessed at Parc Taulí University Hospital. Despite having good control of blood glucose levels, blood pressure, and lipid profile, approximately 10% of the individuals studied showed signs of premature vascular aging-a key factor in the development of cardiovascular and microvascular complications that directly affect quality of life and life expectancy.
Més informació "Abdominal fat is associated with premature vascular aging in type 1 diabetes"
26/01/2026 - Press release
Deaths among patients with acute myocardial infarction before reaching hospital were reduced, during the response by the Medical Emergency System of Catalonia (SEM), by 20% during this period, compared with what would have been expected in the period prior to the implementation of this initiative. Overall, 28-day mortality after suffering a heart attack decreased significantly, falling from 27% of cases to 19%. These findings are highlighted in a study by researchers from the Hospital del Mar Research Institute, in collaboration with Hospital de Sant Pau and Hospital Clínic de Barcelona, which analysed data from 100,000 people who suffered a heart attack in Catalonia between 2008 and 2019.
16/01/2026 - Press release
Researchers from the Hospital del Mar Research Institute and the Vall d'Hebron Institute of Oncology have demonstrated, in animal models, the role played by these cells in the development of cancer cells. The study, published in Science Advances, shows that eliminating these cells at an early stage of tumor growth promotes tumor proliferation and the formation of metastases. By contrast, combining their elimination with an inhibitor of the CCL2 molecule reduces tumor size and eliminates metastases.
16/12/2025 - Press release
It aims to develop the first treatment based on mRNA therapy to boost the efficacy of immunotherapy for this type of tumour. The new company, a spin-off of the Hospital del Mar Research Institute Barcelona, plans to launch its first human clinical trial in 2028 to validate the safety of this approach. The project is led by Drs. Toni Celià-Terrassa and Joan Albanell, pioneers in the development of nanotherapies designed to transform tumours that are resistant to immunotherapy into tumours that are vulnerable to treatment.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
